| Assessment Status | Rapid Review Complete |
| HTA ID | 26044 |
| Drug | Lisocabtagene maraleucel |
| Brand | Breyanzi® |
| Indication | Lisocabtagene maraleucel (Breyanzi®) for the treatment of adult patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have relapsed within 12 months from completion of, or are refractory to, first line immunochemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 07/09/2026 |
| Rapid review completed | 30/09/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that lisocabtagene maraleucel not be considered for reimbursement for this indication at the submitted price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here